Ownership history in CITADEL ADVISORS LLC Β· 8 quarters on record
This page tracks every 13F SEC filing in which CITADEL ADVISORS LLC reported a position in EUDA HEALTH HOLDINGS LTD (EUDA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CITADEL ADVISORS LLC outperformed the S&P 500 by +65.5% annually on this EUDA position. Timing score: 29% (2/7 decisions correct). Average cost basis: $27.19. Maximum drawdown during holding period: β55.1%.
π₯ Exceptional β beat the S&P 500 by 65.5% per year on this position.
7 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 7 add/trim decisions correct
Best entry: $15.20 (2023 Q2) Β· Worst: $77.20 (2024 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
4 adds Β· 4 trims. Bought during 1 of 3 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size